标题
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
作者
关键词
-
出版物
MODERN PATHOLOGY
Volume 29, Issue 8, Pages 824-831
出版商
Springer Nature
发表日期
2016-05-13
DOI
10.1038/modpathol.2016.89
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Crizotinib and Testing for ALK
- (2017) Alice T. Shaw et al. Journal of the National Comprehensive Cancer Network
- Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
- (2016) Xuewen Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic alterations in lung adenocarcinoma
- (2015) Siddhartha Devarakonda et al. LANCET ONCOLOGY
- Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma
- (2015) S. Schmid et al. LUNG CANCER
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers
- (2015) Jin Sung Jang et al. Scientific Reports
- Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
- (2015) Igor Vujic et al. Oncotarget
- ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options
- (2014) Conor E. Steuer et al. CANCER
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
- (2014) Tatsushi Kodama et al. CANCER LETTERS
- The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1
- (2014) J K Yoo et al. CELL DEATH AND DIFFERENTIATION
- Personalized Therapy for Lung Cancer
- (2014) Andre L. Moreira et al. CHEST
- U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
- (2014) S. M. Malik et al. CLINICAL CANCER RESEARCH
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
- (2014) Sara D. Robinson et al. LUNG CANCER
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Characteristics of Lung Cancers Harboring NRAS Mutations
- (2013) K. Ohashi et al. CLINICAL CANCER RESEARCH
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Immunohistochemical study of 36 cases of pulmonary sarcomatoid carcinoma—sensitivity of TTF-1 is superior to napsin
- (2013) Simone B.S.P. Terra et al. HUMAN PATHOLOGY
- Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
- (2013) Tianhong Li et al. JOURNAL OF CLINICAL ONCOLOGY
- The evolving genomic classification of lung cancer
- (2013) David S Shames et al. JOURNAL OF PATHOLOGY
- Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies
- (2013) Yoshihisa Kobayashi et al. Journal of Thoracic Oncology
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- (2013) Takashi Seto et al. LANCET ONCOLOGY
- EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: A case report
- (2013) Greta Alì et al. LUNG CANCER
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases
- (2013) Siyuan Huang et al. World Journal of Surgical Oncology
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- The Value of Biomarkers in Patients With Sarcomatoid Carcinoma of the Lung: Molecular Analysis of 33 Cases
- (2012) Xiangli Jiang et al. Clinical Lung Cancer
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Rafael Lozano et al. LANCET
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Clinicopathological features of lung adenocarcinoma with KRAS mutations
- (2011) Seiichi Kakegawa et al. CANCER
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- (2011) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations
- (2009) G. Konstantinidou et al. CANCER RESEARCH
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now